SCHEMBL4226863

SCHEMBL4226863

CCCCN1CCC(Oc2ccc(C(=O)O)cc2C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.47
KDM4E B2RXH2 3/20 0.47
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
HTR4 Q13639 5/20 0.44
CHRM3 P20309 2/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
ADRA2C P18825 1/20 0.44
HTR1D P28221 1/20 0.44
ADRA1B P35368 1/20 0.44
HTR2B P41595 1/20 0.44
HTR3A P46098 1/20 0.44
UTS2R Q9UKP6 1/20 0.44
KCNH2 Q12809 2/20 0.44
OPRM1 P35372 1/20 0.43
OPRK1 P41145 1/20 0.43
SSTR5 P35346 1/20 0.43
HRH1 P35367 1/20 0.43
CCR3 P51677 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236276 0.89 HRH3 (0.48) HRH3KDM4EUTS2RKCNH2OPRM1
SCHEMBL4237246 0.87 EPHX2 (0.51) MAOAMAOBHTR4CHRM3CHRM4
SCHEMBL4237296 0.87 PDE4A (0.56) HTR4CHRM3CHRM4CHRM5ADRA2C
SCHEMBL4232317 0.87 SSTR5 (0.46) HRH3MAOAMAOBHTR4CHRM3
SCHEMBL4238046 0.85 MAOA (0.47) HRH3KDM4EMAOAMAOBHTR4
SCHEMBL4233582 0.84 SLC6A5 (0.46) KDM4EHTR4CHRM3CHRM4CHRM5
SCHEMBL4233533 0.84 HRH3 (0.54) HRH3KDM4ECHRM3CHRM4CHRM5
SCHEMBL4232026 0.82 SSTR5 (0.53) HRH3MAOAMAOBKCNH2OPRM1
SCHEMBL4233913 0.81 KCNH2 (0.58) KDM4EUTS2RKCNH2OPRM1OPRK1
SCHEMBL10088647 0.81 PDE4B (0.52) HRH3KDM4EKCNH2OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R HRH3 210/4885KDM4E 1604/4885MAOA 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.